chufangao/CTO huggingface dataset:
Clinical trial NCT05179603: A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]
Official title: Phase 2 Non-randomized, Open-label, Multi-cohort, Multicenter Study Assessing the Clinical Benefit of SAR444245 (THOR-707) With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Early discontinuation based on strategic sponsor decision not driven by any safety concerns.
Enrollment: 14.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-07
Primary completion date: 2023-09-14
Completion date: 2024-09-06
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT05243563: Does Steroid Plus CO2 Laser Improve Lichen Sclerosus Symptoms Compared to Steroids Alone?
Official title: A Randomized, Unblinded Trial of Topical Steroids Plus CO2 Laser Compared to Steroids Alone in the Treatment of Vulvovaginal Lichen Sclerosus
Sponsor: University of South Alabama (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Inability to obtain recruitment levels needed for study to continue.
Enrollment: 11.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-04-13
Primary completion date: 2024-06-03
Completion date: 2024-06-03
Plan to share individual participant data: NO
Clinical trial NCT04530448: Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
Official title: Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
Sponsor: West Virginia University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Unable to recruit enough subjects to complete the study. Only 3 subjects enrolled. However, those subjects did not complete the study as the PI terminated the study and data was not collected.
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-05
Primary completion date: 2021-07-15
Completion date: 2021-07-15
Baseline population: Unable to recruit enough subjects to complete the study. Only 3 subjects enrolled. However, those subjects did not complete the study as the PI terminated the study.
Plan to share individual participant data: NO
Clinical trial NCT02026089: Persistence of Varicella Immunity in Hospital Employees Receiving Varicella Vaccine
Official title: Persistence of Varicella Immunity in Hospital Employees Receiving Varicella Vaccine
Sponsor: University of Colorado, Denver (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Unforeseen reduction of recruitment resource.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-31
Primary completion date: 2022-06-30
Completion date: 2022-06-30
Plan to share individual participant data: NO
Clinical trial NCT03330405: Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Official title: A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY(ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the investigational treatments have been moved to a continuation study (NCT05059522).
Enrollment: 223.0 (ACTUAL)
Number of arms: 13.0
Start date: 2017-10-19
Primary completion date: 2022-02-22
Completion date: 2023-01-04
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT04409145: First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations
Official title: Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations
Sponsor: Venthera, Inc., a BridgeBio company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Part 1 complete; Part 2 will not be completed.
Enrollment: 15.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-10-01
Primary completion date: 2022-04-13
Completion date: 2022-04-13
Plan to share individual participant data: NO
Clinical trial NCT03661983: Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder
Official title: A Randomized, Placebo-controlled Trial to Evaluate the Long-term (ie, Maintenance) Efficacy of Oral Aripiprazole in the Treatment of Pediatric Subjects With Tourette's Disorder
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Lack of feasibility for completion of the trial within a reasonable time frame.
Enrollment: 36.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-10-13
Primary completion date: 2020-06-30
Completion date: 2020-06-30
Baseline population: The Enrolled Sample included all participants who entered the open-label stabilization phase.
Limitations and caveats: This trial was terminated early due to the withdrawal of post-marketing commitment (PMC) to FDA. The planned interim analysis was not conducted either.
Plan to share individual participant data: YES
IPD sharing description: Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
IPD time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
IPD access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com
Clinical trial NCT04524026: RIOTC: Reducing the Impact of Ovarian Stimulation. Novel Approaches to Luteal Support in IVF-Study 2
Official title: RIOTC: Reducing the Impact of Ovarian Stimulation. Novel Approaches to Luteal Support in IVF - Study 2
Acronym: RIOTC
Sponsor: Zealand University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 25.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-09-18
Primary completion date: 2020-11-30
Completion date: 2020-11-30
Plan to share individual participant data: NO
Clinical trial NCT04385589: Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure
Official title: Safety and Efficacy of Adding Dapagliflozin and Furosemide in Diabetic Patients (Type 2) With Decompensated Heart Failure With Reduced Ejection Fraction (HFrEF)
Sponsor: Assiut University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 100.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-01
Primary completion date: 2020-12-15
Completion date: 2020-12-20
Plan to share individual participant data: NO
Clinical trial NCT03380546: Acarbose and Prandial Insulin for the Treatment of Gestational Diabetes Mellitus.
Official title: Non-inferiority Between Acarbose and Prandial Insulin for the Treatment of Gestational Diabetes Mellitus: a Randomized Multicenter and Prospective Trial. ACARB-GDM Study.
Acronym: ACARB-GDM
Sponsor: Assistance Publique - Hôpitaux de Paris (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: difficulty in recruiting
Enrollment: 341.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-07-04
Primary completion date: 2023-08-12
Completion date: 2024-02-22
Plan to share individual participant data: NO
Clinical trial NCT04188379: A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
Official title: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX 113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia
Acronym: ADVANCE
Sponsor: argenx (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 131.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-16
Primary completion date: 2022-02-03
Completion date: 2022-02-03
Plan to share individual participant data: NO
Clinical trial NCT03334851: Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis
Official title: A PHASE 1, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, SPONSOR OPEN, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 74.0 (ACTUAL)
Number of arms: 14.0
Start date: 2017-11-17
Primary completion date: 2022-02-15
Completion date: 2022-02-15
Baseline population: Baseline analysis population included all enrolled participants who received at least one dose of study treatment.
Plan to share individual participant data: NO
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT04834310: Postoperative Antibiotics Following Primary and Secondary Breast Augmentation
Official title: Postoperative Antibiotics Following Primary and Secondary Breast Augmentation: A Double-Blinded, Randomized Trial
Sponsor: University of California, Los Angeles (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Do not have adequate funding to proceed with project.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-01
Primary completion date: 2024-05-30
Completion date: 2024-07-30
Plan to share individual participant data: NO
Clinical trial NCT05074888: Сlinical Trial of Efficacy and Safety of Prospekta in the Treatment of Post-COVID-19 Asthenia.
Official title: A Multicenter, Double-blind, Placebo-controlled, Parallel-group, Randomized Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Patients With Post-COVID-19 Asthenia.
Sponsor: Materia Medica Holding (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 676.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-15
Primary completion date: 2022-06-08
Completion date: 2022-06-08
Clinical trial NCT02316002: Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer
Official title: Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer
Sponsor: Abramson Cancer Center at Penn Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 51.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-01-21
Primary completion date: 2018-09-30
Completion date: 2022-12-31
Clinical trial NCT03661424: BATs in Patients With Breast Cancer and Leptomeningeal Metastases
Official title: A Phase I Study of Anti-CD3 x Anti-Her2/Neu (Her2Bi) Armed Activated T Cells (ATC) in Patients With Breast Cancer Leptomeningeal Metastases
Sponsor: University of Virginia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: slow study accrual, partially due to pandemic
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-02-26
Primary completion date: 2021-12-14
Completion date: 2021-12-14
Plan to share individual participant data: NO
Clinical trial NCT03307603: Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer
Official title: A Phase Ib/II Study of Yttrium-90 Radioembolization With Nivolumab for Treatment of Liver and Extra-hepatic Metastases From Colorectal Cancer
Sponsor: Case Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Sponsor chose not to continue
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-12-31
Primary completion date: 2019-03-31
Completion date: 2021-03-31
Clinical trial NCT03367819: Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies
Official title: A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab (SAR650984) in Combination With REGN2810, or Isatuximab Alone, in Patients With Advanced Malignancies
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The study was stopped after interim analysis indicated that overall result was not sufficient to satisfy per-protocol criteria to move forward in metastatic, castration-resistant prostate cancer (mCRPC) and non-small cell lung cancer (NSCLC) cohorts.
Enrollment: 44.0 (ACTUAL)
Number of arms: 6.0
Start date: 2018-01-04
Primary completion date: 2021-03-10
Completion date: 2021-03-10
Baseline population: Analysis was performed on all-treated population which included all participants who signed the study informed consent (IC) and received at least 1 dose (even incomplete) of the study treatments, either isatuximab or REGN2810.
Limitations and caveats: The study was terminated after the interim analysis of the primary endpoint. Few planned outcome measures per-protocol were not analyzed because overall efficacy results were not sufficient at the time of interim analyses of both the cohorts.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT05648006: First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer
Official title: A Prospective, Multicenter, Open, Randomized Controlled Phase II Clinical Study Evaluating Recombinant Oncolytic HSV2（OH2）Therapeutic Injecta(Vero Cell) for Human Use(rHSV2hGM-CSF) in Combination With Capecitabine for First-line Maintenance Therapy in Advanced Colorectal Cancer
Sponsor: Binhui Biopharmaceutical Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Strategy adjustment
Enrollment: 7.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-10-17
Primary completion date: 2024-04-15
Completion date: 2024-04-15
Clinical trial NCT04022057: The Impact of a Preoperative Nerve Block in Foot and Ankle Surgery on the Consumption of Sevoflurane
Official title: The Impact of a Preoperative Nerve Block in Foot and Ankle Surgery on the Consumption of Sevoflurane
Sponsor: University of Alberta (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: COVID-19 Pandemic
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-08-01
Primary completion date: 2020-03-15
Completion date: 2020-03-15
Clinical trial NCT03784599: T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC
Official title: Trastuzumab-emtansine and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC
Acronym: TRAEMOS
Sponsor: The Netherlands Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: insufficient effectiveness
Enrollment: 28.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-12-18
Primary completion date: 2021-05-17
Completion date: 2021-05-17
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03382834: Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Official title: Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 31.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-04-26
Primary completion date: 2018-12-04
Completion date: 2023-07-27
Baseline population: All enrolled participants
Plan to share individual participant data: YES
IPD sharing description: Individual participant data that underlie results in the publication, after deidentification.
IPD time frame: Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by the NIH.
IPD access criteria: With whom?~Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.~For what types of analyses?~To achieve aims in the proposal approved by the AIDS Clinical Trials Group. By what mechanism will data be made available?~Researchers may submit a request for access to data using the AIDS Clinical Trials Group Data Request form at: https://submit.mis.s-3.net/. Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.
Clinical trial NCT05159531: Virtual PrEP: Rendering PrEP Delivery More Efficient
Official title: Virtual PrEP: Rendering PrEP Delivery More Efficient Using an mHealth Intervention and TAF/FTC
Acronym: VPrEP
Sponsor: Unity Health Toronto (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Funding withdrawn
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-05-01
Primary completion date: 2023-06-08
Completion date: 2023-06-08
Plan to share individual participant data: NO
Clinical trial NCT04200651: Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery
Official title: Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery
Acronym: SUSTAIN
Sponsor: The New York Eye Surgery Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: COVID-19 challenges to recruitment
Enrollment: 25.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-13
Primary completion date: 2023-07-12
Completion date: 2023-07-12
Baseline population: 24 eyes from 20 subjects were consented and met criteria for the study (see Participant Flow Overview). However, prior to full baseline assessment and prior to surgery, 6 eyes from 4 subjects dropped out, leaving 18 eyes from 16 subjects. Additionally, given that a mixed-eye sample can impact statistical assumptions of independence, baseline data comparisons were separated between single eyes and fellow-eyes.
Limitations and caveats: Early termination related to COVID-19 recruitment difficulties and loss to follow-up leading to small numbers of eyes analyzed. Length of follow-up limited to 3 months. Use of only three types of minimally invasive glaucoma surgery. Single-site, single-surgeon, open-label design.
Plan to share individual participant data: NO
IPD sharing description: There is not a plan to make IPD available.
Clinical trial NCT04372979: Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.
Official title: Evaluation Of Efficacy Of COVID-19 Convalescent Plasma Versus Standard Plasma In The Early Care Of COVID-19 Patients Hospitalized Outside Intensive Care Units.
Acronym: PLASCOSSA
Sponsor: Direction Centrale du Service de Santé des Armées (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Reluctance of patients and physicians in this transfusion study setting. Blood products have expired. New variants have appeared since the plasma collection period. Some recent publications question the effectiveness of transfusion.
Enrollment: 18.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-14
Primary completion date: 2021-06-01
Completion date: 2021-06-01
Plan to share individual participant data: NO
Clinical trial NCT02358031: A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
Official title: A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 882.0 (ACTUAL)
Number of arms: 3.0
Start date: 2015-03-19
Primary completion date: 2019-02-25
Completion date: 2023-07-19
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT01381211: Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular Carcinoma (HCC)
Official title: Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of HCC: A Multicenter Randomized Controlled Trial (TRACE Trial)
Acronym: TRACE
Sponsor: University Hospital, Ghent (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: based on interim analysis results
Enrollment: 72.0 (ACTUAL)
Number of arms: 2.0
Start date: 2011-09-30
Primary completion date: 2018-03-31
Completion date: 2020-03-31